Drug resistance of Mycobacterium tuberculosis to linezolid and delamanid: a case report from Bukavu, Democratic Republic of Congo

The emergence of resistance is of great concern in the control of TB, especially to the new and repurposed drugs needed for the treatment of rifampicin resistance. We report a patient from South Kivu in the Eastern Democratic Republic of the Congo with primary resistance to delamanid and linezolid without treatment experience with these drugs. The identification of novel resistance mutations raises concerns about the potential global spread and poor outcomes of the WHO-recommended oral treatment regimens, highlighting the need for the urgent rollout of DST.

Authors

Institutions

Publication Details

Journal
BMC Infectious Diseases
Published
2025-07-12
DOI
https://doi.org/10.1186/s12879-025-11348-w
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Drug resistance of Mycobacterium tuberculosis to linezolid and delamanid: a case report from Bukavu, Democratic Republic of Congo

Bertin C Bisimwa, François Hakizayezu, Steven Callens, Leen Rigouts et al.
BMC Infectious Diseases
Tuberculosis Research and Epidemiology
article

Drug resistance of Mycobacterium tuberculosis to linezolid and delamanid: a case report from Bukavu, Democratic Republic of Congo

Bertin C Bisimwa, François Hakizayezu, Steven Callens, Leen Rigouts, Bouke C. de Jong, Maja Kiselinova, Conor Joseph Meehan, Isabel Cuella Martin, Freddy Birembano, Esto Bahizire, Wim Mulders, Jean Claude Semuto Ngabonziza, Michel Kaswa, Valéry Byela, Docteur Runyambo
article en

Abstract

The emergence of resistance is of great concern in the control of TB, especially to the new and repurposed drugs needed for the treatment of rifampicin resistance. We report a patient from South Kivu in the Eastern Democratic Republic of the Congo with primary resistance to delamanid and linezolid without treatment experience with these drugs. The identification of novel resistance mutations raises concerns about the potential global spread and poor outcomes of the WHO-recommended oral treatment regimens, highlighting the need for the urgent rollout of DST.

BMC Infectious DiseasesVol. 25(1)
University of Nairobi (KE), University of Antwerp (BE), Ghent University Hospital (BE), University of Kigali (RW), University of Kinshasa (CD), University of Rwanda (RW), Université Catholique de Bukavu (CD), National Institute of Biomedical Research (CD), Programme National Multisectoriel de Lutte contre le sida (CD), Rwanda Biomedical Center (RW), Nottingham Trent University (GB), Instituut voor Tropische Geneeskunde (BE)
Vlaamse regering
Good health and well-being
Openalex Percentile: Top 79%
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.